Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q6UY14
UPID:
ATL4_HUMAN
Alternative names:
Thrombospondin repeat-containing protein 1
Alternative UPACC:
Q6UY14; B2RTT0; F8WAD0; Q5T5F7; Q6IPM6; Q8N643; Q9HBS6
Background:
ADAMTS-like protein 4, also known as Thrombospondin repeat-containing protein 1, plays a crucial role in the positive regulation of apoptosis and may facilitate FBN1 microfibril biogenesis. This protein's involvement in the structural integrity of connective tissues highlights its importance in cellular processes.
Therapeutic significance:
Linked to ocular abnormalities such as Ectopia lentis 2, isolated, autosomal recessive, and Ectopia lentis et pupillae, ADAMTS-like protein 4's genetic variants offer insights into its pathological roles. Understanding the role of ADAMTS-like protein 4 could open doors to potential therapeutic strategies for these eye conditions.